DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: NOVANTRONE (mitoxantrone)
       *****************************************************
       #Post#: 586--------------------------------------------------
       (Abst.) Lack of efficacy of mitoxantrone in PPMS
   DIR By: agate
       Date: December 12, 2014, 3:20 pm
       ---------------------------------------------------------
       I can't determine how "peer-reviewed" the Journal of
       Neuroimmunology is but this abstract concerns mitoxantrone, and
       there hasn't been much about it lately.
       From PubMed, December 4, 2014:
       --- Quote ---
       > J Neuroimmunol. 2014 Nov 20. pii: S0165-5728(14)00978-3. doi:
       10.1016/j.jneuroim.2014.11.017.
       >
       > Lack of efficacy of mitoxantrone in primary progressive
       multiple sclerosis irrespective of pharmacogenetic factors: A
       multi-center, retrospective analysis
       >
       > Grey Née Cotte S1, Salmen Née Stroet A1, von Ahsen N2, Starck
       M3, Winkelmann A4, Zettl UK4, Comabella M5, Montalban X5, Zipp
       F6, Fleischer V6, Kruse N7, Gold R1, Chan A8.
       >
       > Author information
       >
       > 1Department of Neurology, St. Josef-Hospital, Ruhr University,
       Bochum, Germany.
       > 2Department of Clinical Chemistry, Medical Faculty, University
       of Göttingen, Germany.
       > 3Marianne-Strauß-Klinik, Berg, Germany.
       > 4Department of Neurology, University of Rostock, Germany.
       > 5Department of Neurology-Neuroimmunology, Centre
       d'EsclerosiMúltiple de Catalunya (Cemcat), Institut de
       RecercaValld'Hebron (VHIR), Hospital UniversitariValld´Hebron,
       UniversitatAutònoma de Barcelona, Spain.
       > 6University Medicine Mainz, Johannes Gutenberg University
       Mainz, Department of Neurology, Germany.
       > 7Institute of Neuropathology, University Medical Center
       Göttingen, Germany.
       > 8Department of Neurology, St. Josef-Hospital, Ruhr University,
       Bochum, Germany. Electronic address: Andrew.Chan@rub.de.
       >
       > BACKGROUND:
       >
       > Mitoxantrone is used on an off-label basis in primary
       progressive MS (PPMS). ABC-transporter-genotypes are associated
       with therapeutic response in relapsing/secondary progressive MS
       (RP/SPMS).
       >
       > OBJECTIVE:
       >
       > To evaluate potential pharmacogenetic response markers for
       mitoxantrone in PPMS.
       >
       > METHODS:
       >
       > 41 mitoxantrone-treated PPMS-patients, 155
       mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were
       retrospectively assessed for clinical therapy-response and in
       correlation with four single-nucleotide-polymorphisms in ABCB1-
       and ABCG2-genes.
       >
       > RESULTS:
       >
       > 53.7% PPMS-patients were mitoxantrone-responders, in
       comparison to 78.1% of RP/SPMS-patients (p=0.039). There was no
       association between genotype and treatment response.
       >
       > CONCLUSION:
       >
       > Our data discourages the use of mitoxantrone in PPMS
       regardless of pharmacogenetic response markers previously
       described in RP/SPMS.
       >
       >
       >
       > PMID: 25468777
       --- End Quote ---
       The abstract  can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pubmed/25468777.
       *****************************************************
       Page 1 of 1